Trivalent inactivated influenza vaccine
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01164553 | Oct 2010 → Oct 2012 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01216332 | Oct 2010 → May 2013 | childhood acute lymphoblastic leukemia | Vanderbilt University | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT01436370 | Oct 2011 → Feb 2013 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT01258595 | Nov 2010 → Mar 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00943202 | Aug 2009 → May 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00943878 | Aug 2009 → Apr 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00170547 | Sep 2005 → Jan 2006 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00115531 | Apr → Nov 2005 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT01319955 | Aug 2010 → Apr 2017 | influenza, pneumonia | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00521586 | Sep 2007 → Dec 2013 | influenza | Pfizer | Completed | Met primary |
| Phase 47 trials | ||||||
| Phase 4 | NCT02263027 | Oct 2014 → Jan 2016 | influenza | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 4 | NCT01811823 | Mar → Nov 2014 | HIV infectious disease, influenza, tuberculosis | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 4 | NCT01812980 | May → Jul 2013 | HIV infectious disease, influenza | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 4 | NCT00961337 | Oct 2008 → Mar 2009 | influenza | Centers for Disease Control, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00402805 | Oct 2006 → Feb 2007 | bronchiolitis obliterans syndrome | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT00133523 | Oct 2004 → Jul 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Phase 4 | NCT00161122 | Sep 2003 → Jun 2006 | respiratory tract infectious disorder | UMC Utrecht | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00158665 | Aug → Dec 2004 | influenza | Kaiser Permanente | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT00307177 Comparator | Aug 2004 → Apr 2005 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00766285 Comparator | ? → Sep 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 3 | NCT00492557 Background | Sep 2007 → Feb 2008 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01427309 Comparator | Sep 2011 → May 2013 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| — | NCT01522248 Comparator | Jan → Feb 2012 | — | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| — | NCT00570037 Comparator | Oct 2007 → Apr 2008 | influenza | Duke University | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trivalent inactivated influenza vaccine | “Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly...” NCT00492557 ↗23“Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time” PMID 16991077 ↗ Sep 2006 “Licensed trivalent inactivated influenza vaccine” NCT02263027 ↗ “trivalent inactivated influenza vaccine (TIV)” PMID 22739693 ↗ Jun 2012 |
| Known as | Brand Name: VAXIGRIP | “Brand Name: VAXIGRIP” NCT00961337 ↗ |
| Known as | Fluzone | “Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh...” NCT01164553 ↗2“Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.” NCT00115531 ↗ “Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose.” NCT01436370 ↗ |
| Known as | Fluzone High Dose | “Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose.” NCT01436370 ↗ |
| Known as | seasonal TIV | “received 1 dose of seasonal TIV and 2 doses of 2009 H1N1 vaccine” PMID 22802432 ↗ Jul 2012 |
| Known as | seasonal trivalent inactivated influenza vaccine | “seasonal trivalent inactivated influenza vaccine (TIV; split virion)” PMID 22802432 ↗ Jul 2012 |
| Known as | TIV | “Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly...” NCT00492557 ↗7“Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh...” NCT01164553 ↗ “This is a phase I safety and immunogenicity trial comparing high-dose (HD)trivalent inactivated influenza vaccine (TIV) to standard dose (SD) TIV in pediatric patients with...” NCT01216332 ↗ “We examined serum cytokine kinetics following inactivated trivalent influenza vaccine (TIV) to better understand potential relationships between markers of inflammation and...” PMID 28991404 ↗ Jan 2018 “Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time” PMID 16991077 ↗ Sep 2006 “Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.” NCT00943878 ↗ “seasonal trivalent inactivated influenza vaccine (TIV; split virion)” PMID 22802432 ↗ Jul 2012 “trivalent inactivated influenza vaccine (TIV)” PMID 22739693 ↗ Jun 2012 |
| Modality | Vaccine | “experimental influenza virus vaccine with a dose that is higher than the currently used dose” NCT00115531 ↗ |
| Route | Intramuscular | “will be administered to Arm 1: 200 subjects intramuscularly on day 0.” NCT00115531 ↗ |